PDF(Pubmed)
Abstract：
UNASSIGNED: Stereotactic body radiotherapy (SBRT) is used to treat liver metastases with the intention of ablation. High local control rates were shown. Magnetic resonance imaging guided radiotherapy (MRgRT) provides the opportunity of a marker-less liver SBRT treatment due to the high soft tissue contrast. We report herein on one of the largest cohorts of patients treated with online MRgRT of liver metastases focusing on oncological outcome, toxicity, patient reported outcome measures (PROMs), quality of life.
UNASSIGNED: Patients treated for liver metastases with online MR-guided SBRT at a 1,5 T MR-Linac (Unity, Elekta, Crawley, UK) between March 2019 and December 2021 were included in this prospective study. UK SABR guidelines were used for organs at risk constraints. Oncological endpoints such as survival parameters (overall survival, progression-free survival) and local control as well as patient reported acceptance and quality of life data (EORTC QLQ-C30 questionnaire) were assessed. For toxicity scoring the Common Toxicity Criteria Version 5 were used.
UNASSIGNED: A total of 51 patients with 74 metastases were treated with a median of five fractions. The median applied BED GTV D98 was 84,1 Gy. Median follow-up was 15 months. Local control of the irradiated liver metastasis after 12 months was 89,6%, local control of the liver was 40,3%. Overall survival (OS) after 12 months was 85.1%. Progression free survival (PFS) after 12 months was 22,4%. Local control of the irradiated liver lesion was 100% after three years when a BED ≥100 Gy was reached. The number of treated lesions did not impact local control neither of the treated or of the hepatic control. Patient acceptance of online MRgSBRT was high. There were no acute grade ≥ 3 toxicities. Quality of life data showed no significant difference comparing baseline and follow-up data.
UNASSIGNED: Online MR guided radiotherapy is a noninvasive, well-tolerated and effective treatment for liver metastases. Further prospective trials with the goal to define patients who actually benefit most from an online adaptive workflow are currently ongoing.
UNASSIGNED: Patients treated for liver metastases with online MR-guided SBRT at a 1,5 T MR-Linac (Unity, Elekta, Crawley, UK) between March 2019 and December 2021 were included in this prospective study. UK SABR guidelines were used for organs at risk constraints. Oncological endpoints such as survival parameters (overall survival, progression-free survival) and local control as well as patient reported acceptance and quality of life data (EORTC QLQ-C30 questionnaire) were assessed. For toxicity scoring the Common Toxicity Criteria Version 5 were used.
UNASSIGNED: A total of 51 patients with 74 metastases were treated with a median of five fractions. The median applied BED GTV D98 was 84,1 Gy. Median follow-up was 15 months. Local control of the irradiated liver metastasis after 12 months was 89,6%, local control of the liver was 40,3%. Overall survival (OS) after 12 months was 85.1%. Progression free survival (PFS) after 12 months was 22,4%. Local control of the irradiated liver lesion was 100% after three years when a BED ≥100 Gy was reached. The number of treated lesions did not impact local control neither of the treated or of the hepatic control. Patient acceptance of online MRgSBRT was high. There were no acute grade ≥ 3 toxicities. Quality of life data showed no significant difference comparing baseline and follow-up data.
UNASSIGNED: Online MR guided radiotherapy is a noninvasive, well-tolerated and effective treatment for liver metastases. Further prospective trials with the goal to define patients who actually benefit most from an online adaptive workflow are currently ongoing.
摘要：
UNASSIGNED：立体定向放疗（SBRT）用于消融目的治疗肝转移。显示了较高的局部控制率。由于较高的软组织对比度，磁共振成像引导放射治疗（MRgRT）提供了无标记肝脏SBRT治疗的机会。我们在此报告了最大的患者队列之一，关注肿瘤结果的在线MRgRT治疗肝转移，毒性,患者报告结果测量(PROM)，生活质量。
UNASSIGNED：在1,5TMR-Linac（Unity，Elekta,克劳利,英国)2019年3月至2021年12月被纳入这项前瞻性研究。英国SABR指南用于有风险的器官限制。肿瘤终点，如生存参数(总生存率，评估了无进展生存期）和局部控制以及患者报告的接受度和生活质量数据（EORTCQLQ-C30问卷）。对于毒性评分,使用通用毒性标准第5版。
UNASSIGNED：共有51例74个转移灶的患者接受治疗，中位数为5个分数。应用BEDGTVD98的中位数为84,1Gy。中位随访时间为15个月。12个月后照射肝转移的局部控制为89,6％，肝脏的局部控制率为40,3%。12个月后总生存率（OS）为85.1%。12个月后无进展生存率（PFS）为22,4％。三年后，当达到BED≥100Gy时，辐照肝脏病变的局部控制为100％。治疗的病变数量不影响治疗或肝对照的局部对照。患者对在线MRgSBRT的接受度很高。无急性≥3级毒性。生活质量数据与基线和随访数据相比没有显着差异。
UNASSIGNED：在线MR引导放射治疗是非侵入性，对肝转移有良好的耐受性和有效的治疗。目前正在进行进一步的前瞻性试验，目的是确定实际上从在线自适应工作流程中受益最大的患者。
UNASSIGNED：在1,5TMR-Linac（Unity，Elekta,克劳利,英国)2019年3月至2021年12月被纳入这项前瞻性研究。英国SABR指南用于有风险的器官限制。肿瘤终点，如生存参数(总生存率，评估了无进展生存期）和局部控制以及患者报告的接受度和生活质量数据（EORTCQLQ-C30问卷）。对于毒性评分,使用通用毒性标准第5版。
UNASSIGNED：共有51例74个转移灶的患者接受治疗，中位数为5个分数。应用BEDGTVD98的中位数为84,1Gy。中位随访时间为15个月。12个月后照射肝转移的局部控制为89,6％，肝脏的局部控制率为40,3%。12个月后总生存率（OS）为85.1%。12个月后无进展生存率（PFS）为22,4％。三年后，当达到BED≥100Gy时，辐照肝脏病变的局部控制为100％。治疗的病变数量不影响治疗或肝对照的局部对照。患者对在线MRgSBRT的接受度很高。无急性≥3级毒性。生活质量数据与基线和随访数据相比没有显着差异。
UNASSIGNED：在线MR引导放射治疗是非侵入性，对肝转移有良好的耐受性和有效的治疗。目前正在进行进一步的前瞻性试验，目的是确定实际上从在线自适应工作流程中受益最大的患者。
